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EDITORIAL REVIEW
Proteolytic enzymes as mediators of glomerular injury
Despite significant advances in our understanding of the
pathogenesis of glomerular injury, the specific mechanisms
responsible for the pathological changes in glomerular structure
and function which occur in glomerular disease remain poorly
understood. Several diverse lines of evidence, including studies
with purified proteinases, studies with freshly isolated glomeruli
and intact cells, and cells in culture, as well as recent in vivo
studies indicate that proteolytic enzymes play important roles
as mediators of glomerular injury. The concept of proteolytic
enzymes as mediators of glomerular injury is not new. The
ability of polymorphonuclear leukocyte (PMN)-derived pro-
teinases to degrade glomerular basement membrane (GBM) in
vitro coupled with the PMN-dependence of certain types of
glomerulonephritis led Cochrane and coworkers in the mid-
sixties to postulate that neutrophil-derived proteinases cause
glomerular injury by proteolysis of the GBM [1—31. Since then,
a large number of studies have provided support for this
hypothesis. In addition, recent studies documenting the pres-
ence of GBM-degrading proteinases in glomeruli, plasma, and a
variety of other circulating cells indicate that GBM damage can
also be mediated by proteinases originating from these sources
as well. Thus proteinase-mediated GBM damage may be an
important mechanism of glomerular injury in leukocyte-inde-
pendent as well as leukocyte-dependent glomerular diseases.
Furthermore, recent studies suggest that proteolytic enzymes
may contribute to glomerular injury by mechanisms indepen-
dent of GBM damage. Such mechanisms include: proteolysis of
non-GBM proteins; proteinase-mediated alterations in the pro-
duction of key glomerular metabolites; and proteinase-induced
effects on cellular proliferation. In the present review, we
attempt to bring together a large body of diverse information
derived from in vitro and in vivo studies, which supports a
pathogenic role for proteolytic enzymes in glomerular injury.
Proteolytic enzymes: Nomenclature and classification
Proteolytic enzymes, (peptidases) are classified as exo- or
endopeptidases. Exopeptidases are proteinases which cleave
peptide bonds close to the end of a polypeptide chain. Endopep-
tidases (also referred to as proteinases and proteases) cleave
internal peptide bonds. Although many exopeptidases are
present in the kidney and may play important roles in glomer-
ular injury, most studies concerning the role of proteolytic
enzymes in glomerular injury have focused on endopeptidases.
In contrast to most enzymes, which are named and classified
according to their substrate and the type of reaction catalyzed
(such as alcohol dehydrogenase), endopeptidases are classified
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according to their catalytic mechanisms and named for the
essential catalytic component (usually an amino acid) in their
active site [4]. Table I lists the four classes of endopeptidases
and some general properties of each class.
Potential sources of proteolytic enzymes for glomerular injury
With few exceptions, a proteolytic enzyme must have assess
to the glomerulus in order to produce glomerular injury. As
mentioned above, the PMN has long been recognized as a
source of proteolytic enzymes available for glomerular injury
[1—3, 5]. However, other circulating blood cells such as mono-
cytes, macrophages, and platelets contain a variety of proteo-
lytic enzymes [6] and thus must also be included as potential
sources of proteolytic enzymes. In addition, recent studies from
our laboratory have demonstrated that glomeruli contain sev-
eral proteolytic enzymes, most notably metalloproteinases [7,
8] and cysteine proteinases [9], which may also contribute to
glomerular injury. Thus the glomerulus itself, including mesan-
gial, endothelial, and epithelial cells constitutes a second im-
portant source of proteolytic enzymes available for glomerular
injury. A third potential source of proteolytic enzymes is the
plasma. Well-documented proteolytic enzymes in plasma in-
clude components of the coagulation, complement, and fibrin-
olytic systems. Although these plasma proteinases circulate as
zymogens (inactive forms) and are usually activated only as
part of well-regulated physiological processes, several lines of
evidence suggest that they participate in processes which may
contribute to glomerular injury. For example, thrombin appears
to play an important role in the intraglomerular fibrin deposition
which occurs in certain types of glomerulonephritis [10]. In
addition, recent studies suggest that plasmin, generated from
plasma plasminogen by glomerular plasminogen activators,
may also play an important role(s) in glomerular injury. Table 2
includes a list of several proteinases of potential interest to
glomerular injury as well as potential sources of each of these
proteinases.
It is important to recognize that interactions between proteo-
lytic enzymes, including those from different sources, can and
do occur. For example, Gavrilovic et al [11—13] have demon-
strated that the degradation of type I collagen films by phorbol
myristate acetate- or interleukin-l-stimulated cells in culture is
dependent on the presence of plasminogen in the medium.
However, collagen degradation was inhibited by the collage-
nase inhibitors TIMP (tissue inhibitor of metalloproteinases)
and antibodies to collagenase. Based on these observations,
these workers postulated that plasminogen activator(s), pro-
duced by the stimulated cells, converted plasminogen to plas-
mm which in turn activated procollagenase (also produced by
the cells) which is directly responsible for the collagen degra-
dation. Clearly the potential for such interactions (and others as
discussed below) must be recognized in the design of experi-
mental protocols as well as the interpretation of results.
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Table 1. Classes and some general properties of endopeptidasesa
Property Serine Cysteine Aspartic Metallo
Old name Serine Thiol Carboxyl Metallo
Enzyme commission # 3.4.21 3.4.22 3.4.23 3.4.24
Active site component Serine Cysteine Aspartic acid Zn2
pH rangeb 79 3.7 2—6 5—9
Inhibitors (in vitro) PMSF, SBTI, DIFP E-64, lodoacetate, Pepstatin EDTA, o-phen-
organo-mercurials anthroline
Inhibitors (in vivo) Plasma proteinase Cystatins, a1-cysteine Unknown TIMP-1, TIMP-
inhibitorsc proteinase inhibitor 2
Location Intra- and extra- Lysosomes' Lysosomes Intra- and
cellular extracellular
Latent forms Yes Yes No Yes
Examples Elastase, plasmin Cathepsins B & L Cathepsin D Gelatinase,
type IV
collagenase
a Adopted from [4]
b Varies with substrate and assay conditions
a1-Protenase inhibitor, a,-antiplasmin, a2.macroglobulin, etc. [106]d Except calpain, the cytosolic & membrane-bound Ca2-dependent cysteine proteinase [155]
Table 2. Proteolytic enzymes potentially involved as mediators of glomerular injury
Proposed mechanism of glomerular injurya
Proteolysis Proteolysis of Altered glomerular
Proteinase Class Source of GBM nonGBM proteins metabolism
Elastase & Serine Leukocytes 5, 33—40, 57, 41, 42, 85, 93, 109, 23, 25, 26, 125, 131
cathepsinG 58,60,61 112, 114, 115
Plasmin Serine Plasma 94—99 10—13, 102—104
Thrombin Serine Plasma 95 10 20—22, 24, 27, 29, 138
Gelatinase Metallo Leukocytes 41, 56, 59—61 113
Gelatinase Metallo Glomeruli 50—52
Glomerular Metallo Glomeruli 7. 8
metalloproteinase(s)
Cathepsins B & L Cysteine Glomeruli 9, 67—71 102, 111
a Numbers refer to reference number
Potential mechanisms of proteinase-mediated glomerular injury
In vitro studies have delineated a variety of biological effects
of proteolytic enzymes of potential relevance to glomerular
injury. For purposes of discussion, we have grouped these
effects into three general categories of potential mechanisms of
proteinase-mediated glomerular injury: proteolysis of the GEM;
proteolysis of non-GBM proteins; and proteinase-mediated
alterations in glomerular metabolism, (including effects on cell
proliferation). It is important to point out that these mecha-
nisms are not mutually exclusive. As described below and listed
in Table 2, the ability of several proteolytic enzymes (such as
elastase, plasmin) to produce effects described in more than one
category is well documented.
Proteolvsis of the GBM
The GBM is the major filtration barrier of the glomerulus
restricting the passage of plasma proteins into the urine [14—16].
The hallmark of glomerular disease is proteinuria resulting from
an increase in the permeability of the GBM to plasma proteins.
Thus, possibly the most obvious mechanism by which proteo-
lytic enzymes can cause glomerular injury is degradation of the
GBM. The GBM is composed primarily of type IV collagen,
with lesser amounts of laminin, entactin (nidogen), and heparan
sulfate proteoglycan. Fibronectin, collagen types V and VII,
osteonectin (SPARC, BM-40) and several other proteins are
also present in GBM, although it is presently unclear whether
these proteins are intrinsic GBM components or passively
accumulated following GBM synthesis [17—19]. It should be
noted that each component of the GBM, including heparan
sulfate proteoglycan, is susceptible in vitro to proteolysis by
one or more proteinases available to or present in normal
glomeruli. As discussed in detail below, a large body of evi-
dence suggests that proteinase-mediated GBM damage is an
important mechanism of glomerular injury.
Proteolysis of non-GBM proteins
In addition to GBM degradation, proteolysis of non-GBM
proteins can also occur. For example, inactivation of proteinase
inhibitors could result in glomerular injury mediated by uncon-
trolled proteinase activity. In vitro the ability of proteolytic
enzymes to inactivate proteinase inhibitors is well documented
(see below) and raises the possibility that such inactivation may
represent an additional mechanism by which proteinases could
contribute to glomerular injury.
In contrast to the proteolysis of GBM and proteinase inhibi-
tors, which results in loss of function, proteolysis of many
proteins results in increased activity of the target protein.
Pertinent examples are the proteinase-mediated activation of
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zymogens, the inactive forms of many enzymes. Normally
zymogen activation occurs by limited proteolysis, earned out
by a specific proteinase as part of a well controlled physiolog-
ical process, such as coagulation or fibrinolysis. However,
"inappropriate" activation of zymogens does occur and can
lead to pathological changes, as evidenced by intraglomerular
fibnn deposition resulting from the localized activation of
thrombin [10].
Thus proteolysis of non-GBM proteins, resulting in either
activation or inactivation of the target protein, represents a
second potential mechanism of proteinase-mediated glomerular
injury.
Proteinase-mediated alterations in glomerular metabolism
The ability of proteolytic enzymes to influence the production
of several key metabolites, autocrine mediators, and intracel-
lular signalling agents is well documented. For example, addi-
tion of proteolytic enzymes to intact cells in vitro, has resulted
in altered production and/or secretion of cyclic nucleotides [20,
21], prostaglandins [22—24], platelet activating factor [25], Ca2
flux and inositol polyphosphate synthesis [26, 27], adenine
nucleotides [23], and reactive oxygen metabolites [28]. Each of
these metabolites is postulated to play an important role in
glomerular pathophysiology. In addition, recent studies [27, 29]
indicate that certain proteolytic enzymes stimulate the prolifer-
ation of cultured glomerular cells. Although only limited data is
available documenting altered metabolism in intact glomeruli or
glomerular cells, similarities in the pathways for the production
and catabolism of these metabolites among various tissues and
the well-documented ability of proteinases to alter metabolism
in other tissues suggests that this may be an important mecha-
nism of proteinase-mediated glomerular injury.
In vitro evidence for proteinase-mediated glomerular injury
Proteolysis of GBM and GBM components
GBM degradation in leukocyte-dependent glomerulonephri-
us. Leukocytes contain proteinases in each of the four classes
[6] which have been shown to effectively degrade GBM in vitro
under appropriate conditions. However, several lines of evi-
dence suggest that the serine proteinases elastase and cathepsin
G and the metalloproteinase gelatinase are the leukocyte pro-
teinases most likely to contribute to GBM damage in vivo.
Elastase and cathepsin G are well characterized serine pro-
teinases [reviewed in 30—32] present in neutrophils. In addition,
proteinases with properties similar to elastase and cathepsin G
have been reported in several tissues and cells types, including
macrophages, monocytes, and platelets [30—32]. Three proper-
ties of elastase and cathepsin G are of particular interest with
respect to their ability to damage the GBM: their neutral pH
optimum which facilitates their action in neutral pH environ-
ments such as the plasma-GBM interface; their positive charge
at plasma pH (pls = 9 to 11) which facilitates electrostatic
binding to the negatively charged GBM; and their relatively low
molecular weights (27 to 35 kDa) which promotes penetration
into the GBM lattice and possibly allows them to escape from
higher molecular weight plasma proteinase inhibitors. Thus the
physical properties of these proteinases combined with their
broad substrate specificity (see below) render them ideal can-
didates for mediators of glomerular injury by damage to the
GBM.
GBM degradation at neutral pH by neutrophil granule ex-
tracts (now known to contain large amounts of elastase and
cathepsin G) was first reported by Janoff and Zeligs [5]. This
observation was confirmed and extended in subsequent studies
by Davies, Coles and Hughes [33], who demonstrated that
lysates of human PMN or monocytes as well as highly-purified
human PMN elastase and cathepsin 0 could effectively degrade
GBM at neutral pH in vitro. In addition, neutrophil granule
extracts, purified elastase, and/or cathepsin 0 have been shown
to degrade specific components of the GBM including proteo-
glycans [34—36], fibronectin [37, 38]; and type IV collagen [39,
40].
Neutrophils contain two other major neutral proteinases: the
metalloproteinases, collagenase and a 92-95 kDa gelatinase
[41—45]. This gelatinase appears similar to the type IV collage-
nase present in several tumor cell lines [41, 46], but is a distinct
gene product from the 72 kDa gelatinase present in connective
tissue cells [47—49] and cultured mesangial cells [50—52]. Since
collagenase is relatively specific for collagen types I, II, III,
which are not present in significant amounts in GBM, a major
role for this metalloproteinase in GBM degradation appears
unlikely. However, Lubec and coworkers [53, 54] have re-
ported increased collagenase activity in kidneys obtained from
rats with antiGBM antibody disease [53] and immune complex
glomerulonephritis [54].
Gelatinases (type IV collagenases) are named because of
their ability to degrade gelatin (denatured type I collagen) in
vitro [42—45, 47, 48]. In vivo, gelatinases are postulated to play
important roles in the degradation of type IV collagen, the
major protein component of basement membranes [41, 45,
50—52, 55]. The ability of highly-purified human PMN gelatinase
to degrade in vitro collagen types IV and V as well as fragments
of type I (generated by collagenase) is well documented [41—46,
49]. PMN gelatinase can also degrade intact GBM at neutral pH
(pH range 6.0 to 8.6) as shown by studies from our laboratory
[56]. Compared to gelatinase (human PMN), collagenase (hu-
man fibroblasts) was nearly inactive in the degradation of intact
GBM [56].
Several studies have extended these observations using stim-
ulated intact neutrophils. Bray, Hume and Robinson [57] have
reported that rabbit neutrophils degrade GBM in vitro at neutral
pH. The amount of degradation was increased when the GBM
was pretreated with antiGBM antibodies. Soya bean trypsin
inhibitor and alpha-l-proteinase inhibitor (serine proteinase
inhibitors) inhibited GBM degradation suggesting the involve-
ment of elastase and/or cathepsin G. Vissers, Winterbourn and
Hunt [58] have examined GBM degradation by neutrophils
using "model systems" consisting of intact human neutrophils
incubated with isolated human GBM impregnated with either
nonspecific IgG or albumin-antialbumin immune complexes.
GBM degradation was markedly inhibited by the serine protein-
ase inhibitor phenylmethane sulfonylfluoride (PMSF), suggest-
ing that elastase and/or cathepsin G account for most of the
GBM degradation in this system. We have shown [59] that
GBM degradation by phorbol myristate acetate-stimulated
PMN is mediated by activation of a metalloproteinase (possibly
gelatinase) which is activated by hypochlorous acid (or a similar
oxidant) generated by the PMN myeloperoxidase-H202-halide
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system. Using their in vitro model of immune complex GBM
injury (see above), Vissers and Winterbourn [60] estimated that
neutrophil gelatinase accounted for approximately 30% of the
GBM degradation with elastase/cathepsin G responsible for the
remainder. In a subsequent study comparing GBM degradation
by human neutrophils and monocytes, Vissers et al [61] ob-
served that GBM degradation by monocytes was inhibited
nearly equally by PMSF and o-phenanthroline, suggesting that
both serine (elastase, cathepsin G) and metalloproteinases
(gelatinase) were involved.
Taken together, these studies leave little doubt concerning
the ability of leukocyte proteinases to degrade GBM in vitro.
Coupled with the in vivo studies discussed below they provide
strong support for proteinase-mediated GBM degradation as a
potentially important mechanism of glomerular injury in those
types of glomerular disease characterized by significant leuko-
cyte infiltration.
GBM degradation in leukocyte-independent glomerulone-
phritis. Several types of glomerular disease, including both
experimentally-induced and human glomerulonephritis, lack
significant leukocyte involvement. Thus leukocytes can not
serve as major sources of proteolytic enzymes for glomerular
injury in these types of glomerular disease. Recent studies have
documented the presence of GBM-degrading proteinases in
freshly isolated glomeruli and cultured glomerular cells, raising
the possibility that endogenous glomerular proteinases may be
responsible for GBM damage in these types of glomerulonephri-
tis. Although glomeruli contain proteinases from each major
class, published studies to date suggest that endogenous gb-
merular metalloproteinases and cysteine proteinases may be the
most important as mediators of GBM damage in leukocyte-
independent GN.
Metalloproteinases. Lovett and coworkers have identified,
characterized, and purified a gelatinase, which is present in the
medium (but not the cells) obtained from cultured rat [50, 51]
and human [52] mesangial cells. Similar to other matrix-degrad-
ing metalloproteinases, both the rat and human mesangial cell
gelatinase are synthesized and secreted as inactive zymogens
which can be activated in vitro by aminophenyl mercuric
acetate (APMA) or limited proteolysis with trypsin [50—52]. The
physiological activator(s) of latent gelatinase are unknown. The
purified gelatinase from either species: had a molecular weight
of 66 to 68 kDa; was optimally active at neutral pH; and
degraded intact GBM, soluble type IV collagen, and gelatin but
not fibronectin, albumin, proteoglycan, or interstitial collagen
(types I, II, and III). These data suggest that the mesangial cell
gelatinase is similar to the 72 kDa gelatinase found in connec-
tive tissue cells [47—49]. These workers also reported [52] that
cultured human mesangial cells secrete a protein inhibitor of
gelatinase with the characteristics of TIMP-I (tissue inhibitor of
metalloproteinases). TIMP- 1 [62] and TIMP-2 [63—65] are func-
tionally similar but distinct gene products thought to play major
roles in the physiological control of gelatinase activity [11—13,
62]. Lovett and coworkers reported that immunohistochemical
staining of glomeruli demonstrated the presence of both gelat-
inase and TIMP in the mesangial area of human biopsy speci-
mens [52].
Studies from our laboratory [7, 8] have documented that
glomeruli isolated from normal rats also contain one or more
GBM-degrading metalloproteinases. Incubation of freshly iso-
lated rat glomeruli with intact GBM at pH 7.5 resulted in
significant GBM degradation as measured by hydroxyproline
release [7]. GBM degradation was markedly inhibited by the
metalloproteinase inhibitors, EDTA and o-phenanthroline, but
unaffected by inhibitors of serine (PMSF, leupeptin, alpha-1-PI,
SBTI) or cysteine proteinases (E-64, leupeptin), documenting
that metalloproteinase activity was responsible for the GBM
degradation. In a separate study [8] we have characterized a
gelatin-degrading metalloproteinase activity present in freshly
isolated rat glomeruli. Comparison of the properties of this
metalloproteinase (membrane-associated; molecular weight =
116 to 120 kDa; lack of inhibition by TIMP, lack of activation by
APMA) with those of other well characterized matrix metallo-
proteinases (such as, gelatinase, type IV collagenase, stromel-
ysin) indicates that this glomerular metalloproteinase is distinct
from these metalloproteinases including the mesangial cell
gelatinase [50—52]. Whether the GBM and gelatin degrading
proteinases present in isolated rat glomeruli are the same or
separate enzymes is unclear at the present time.
Although direct evidence linking endogenous glomerular met-
alloproteinases to GBM damage (or other types of glomerular
injury) in vivo has not been reported, their ability to act at
neutral pH and to degrade GBM suggests an important role for
these proteinases in glomerular pathophysiology.
Cysteine proteinases. Cysteine proteinases are a diverse
class of lysosomal enzymes with a relatively broad substrate
specificity and acid pH optima [66]. Among the best character-
ized of the cysteine proteinases are Cathepsins B, H, and L.
The ability of highly purified cathepsins B and L to degrade
intact GBM in vitro has been reported by our lab [67] as well as
by Davies and coworkers [68—70]. In our studies [67], cathepsin
L was more effective in GBM degradation than several other
proteinases. In addition to intact GBM, purified cysteine pro-
teinases have been shown in vitro to degrade purified GBM
components including collagens types IV, and V (B and L: [69,
70], proteoglycan (B, H, and L: [69, 71]; and laminin, (B and L:
[69].
Several lines of evidence, including enzyme activity [9, 72],
immunohistochemistry [73, 74], and fluorescence microscopy
[9], have established the presence of cathepsins B, H, and/or L
in glomeruli isolated from normal rats. Furthermore, we have
recently demonstrated the ability of isolated rat glomeruli to
utilize endogenous cysteine proteinases to degrade intact GBM
in vitro [9].
These studies document the ability of endogenous glomerular
cysteine proteinases to degrade GBM and GBM components in
vitro. However, most cysteine proteinases, including those
documented to be present in glomeruli, are relativley inactive at
neutral pH [9, 66, 67]. Thus special conditions (for example, an
acidified microenvironment) must be envisioned for these pro-
teinases to effectively act in the neutral pH of the glomerular
capillary loop. Although such conditions have not been clari-
fied, these data coupled with the beneficial effects of cysteine
proteinase inhibitors in an experimental model of glomerular
disease (see below) indicate an important role for cysteine
proteinases in the pathogenesis of glomerular disease.
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Urinary excretion of GBM components and proteolytic enzymes
in glomerulonephritis
If proteinase-mediated GBM damage is indeed a mechanism
of glomerular injury in vivo, one might expect to find increased
amounts of GBM components and proteinase activity in the
urine obtained from patients and animals with glomerulonephri-
tis. Such results have been reported in both leukocyte-depen-
dent and leukocyte-independent types of glomerulonephritis,
including experimentally-induced antiGBM antibody disease [3,
75—77] and puromycin aminonucleoside-induced glomerulone-
phritis [78—81]. Similar results have also been reported for
patients with various types of glomerulonephritis, including
diffuse proliferative glomerulonephritis [82], systemic lupus and
membranous glomerulonephritis [83], and acute post-strep gb-
merulonephritis [84]. Taken together, these studies provide
further support for proteinase-mediated GBM damage as a
potential mechanism of glomerular injury.
A summary of the evidence supporting GBM degradation as
an important mechanism of proteinase-mediated gbomerular
injury is presented in Table 2.
Proteolysis of non-GBM proteins
In addition to the protein components of the GBM, a variety
of structurally and/or functionally important intra- and extra-
cellular proteins (for example, receptors, cytoskeletal proteins,
enzymes, etc.) are susceptible to proteolysis by proteolytic
enzymes. It is important to point out that proteolysis of such
proteins may result in either activation or inactivation of the
target protein. Of particular interest with respect to proteinase-
mediated glomerular injury is the inactivation of proteinase
inhibitors and the activation of latent proteolytic enzymes
(zymogens). Although most of the examples presented below
involve proteinases and target proteins from other tissues, the
availability of similar proteinases and protein targets in glomer-
uli raises the possibility that these interactions may occur in
glomeruli as well.
Activation of latent proteinases. The ability of proteolytic
enzymes to activate other enzymes, often latent proteinases
(zymogens) themselves, is well documented. Although all
classes of proteolytic enzymes have been documented to acti-
vate one or more proteinases, activation by serine proteinases
appears to be the most common and offers the greatest potential
with respect to glomerular injury. Because of their many effects
potentially relevant to glomerular injury, the activation of latent
gelatinase (leukocyte or mesangial cell) and the conversion of
plasminogen to plasmin are of particular interest in this regard.
Both elastase [85] and cathepsin G [421 have been reported to
activate latent leukocyte gelatinase in vitro [see however, 86].
Although the mesangial cell gelatinase is a distinct gene product
from the leukocyte gelatinase [46], the ability of a variety of
agents (SDS, organomercurials, trypsin) to activate either of
these gelatinases indicates similarities in their activation mech-
anisms and raises the possibility that elastase and/or cathepsin
G may also activate latent mesangial cell gelatinase. Such
interactions could represent an important mechanism for the
activation of gelatinase in both leukocyte-dependent and inde-
pendent types of glomerulonephritis.
Several lines of evidence suggest that plasmin, produced
from plasminogen by plasminogen activators, may be an impor-
tant mediator of glomerular injury. Intraglomerular fibrin dep-
osition is thought to play an important role in the development
and progression of several types of experimental as well as
human glomerulonephritis [10]. Clearly the ability of the gb-
merulus to influence fibrin deposition via fibrinolysis may play
an important role in this process. The presence of fibrinolytic
activity in the glomerulus is well documented and apparently
mediated by the conversion of plasminogen to plasmin [87—89].
Both tPA and uPA type plasminogen activators have been
identified in glomerular endothelial, epithelial and/or mesangial
cells [90—92]. In addition, Machovich and Owen [93] have
reported that neutrophil elastase enhances the rate of plasmin-
ogen activation by two or more orders of magnitude by a
combination of effects involving increased susceptability of
plasminogen to plasminogen activators and inactivation of
alpha-2-antiplasmin.
In addition to its role in fibrinolysis, plasmin has other effects
of potential relevance to glomerular injury. The ability of
plasmin to degrade components of the GBM, including proteo-
glycan [94]; the glycoproteins laminin and fibronectin [95—98];
and type IV collagen [991 has also been reported. Jones and
coworkers [100, 101] have reported that glycoproteins markedly
inhibit the degradation of collagen and elastin present in the
extracellular matrix secreted by smooth muscle cells in culture
and that plasmin, by degrading these glycoproteins, accelerated
the rate of collagen and elastin degradation. Thus plasmin may
accelerate the degradation of GBM collagen (by gelatinase or
elastase for example) by removal of the glycoprotein compo-
nents of GBM. In addition to these effects, plasmin may
activate latent gelatinase. Based on the ability of plasmin to
activate latent collagenase [11—13, 102—104] and apparent simi-
larities in the activation mechanisms of latent gelatinase and
latent collagenase by other agents [105], the possibility that
plasmin may activiate latent gelatinase must also be considered.
However, Nagase and coworkers [86] failed to observe activa-
tion of latent fibroblast gelatinase by purified plasmin.
The high concentration of plasminogen in the plasma, its
continuous presence in the glomerulus, the production of plas-
minogen activators by glomerular cells, and the ability of
plasmin to produce a variety of biological effects potentially
related to gbomerular injury suggest an important role for this
proteinase as a mediator of glomerular injury.
Inactivation of proteinase inhibitors. Several inhibitors of
proteolytic enzymes are well characterized proteins which are
thought to play important roles in the regulation of proteinase
activity in vivo. Such inhibitors include the plasma proteinase
inhibitors such as alpha-l-proteinase inhibitor, alpha-2-antiplas-
mm, alpha-l-cysteine proteinase inhibitor, etc. [reviewed in
106], the cystatins, intracellular inhibitors of cysteine protein-
ases [reviewed in 107], and TIMP (tissue inhibitor of metallo-
proteinases) [63—65, reviewed in 62]. As proteins, these inhibi-
tors are susceptible to degradation by proteolytic enzymes. A
good example of the importance of proteinase inhibitors in vivo
is demonstrated by the high incidence of emphysema, appar-
ently mediated by neutrophil elastase, which occurs in patients
with severe alpha-l-proteinase inhibitor (alpha-l-PI) deficiency
[108]. Clearly, decreased levels of proteinase inhibitors (either
systemic or localized to the pericellular microenvironment)
potentially could result in gbomerular injury via excess proteo-
lytic enzyme activity. Proteolytic enzymes have been reported
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to inactivate several proteinase inhibitors including Cl macti-
vator [1091 and antithrombin III [1101. However, based on the
effects of elastase, gelatinase, and plasmin on GBM compo-
nents (as discussed above) and on the production of key
metabolites (see below), inactivation of the inhibitors of these
proteinases (alpha-1-PI, TIMP, and alpha-2-antiplasmin, re-
spectively) is of particular interest here. Proteolytic inactivation
of alpha-l-PI in vitro by cathepsin L [Ill], macrophage elastase
[112], and a metalloproteinase secreted by PMA-stimulated
human neutrophis [113] has been reported. Okada et al [114]
have reported that in vitro human neutrophil elastase, trypsin,
and chymotrypsin (but not cathepsin G, pancreatic elastase, or
plasmin) effectively inactivate TIMP- 1, a major physiological
inhibitor of gelatinase and other matrix metalloproteinases
[11—13, 62—65]. Neutrophil elastase has been reported to inac-
tivate alpha-2-antiplasmin [109, 1151. That these or similar
reactions take place in vivo is indicated by the observation that
proteolyzed alpha-1-PI has been recovered from the sites of
inflammation [116, 117]. Although the pathophysiological sig-
nificance of these observations to glomerular injury remains to
be established, the presence of several of these proteinases in
glomeruli (either intrinsically or via infiltrating leukocytes)
raises the possibility that inactivation of one or more proteinase
inhibitors could result in increased activity of the corresponding
proteinase with subsequent deleterious effects on glomerular
structure and function. In keeping with this idea, it is interesting
to note that several cases of glomerulonephritis associated with
severe genetic deficiency of alpha- 1-PI have been reported
[118—121].
The ability of proteinases to activate latent proteinases and
inactivate the corresponding proteinase inhibitors raises the
possibility of a potentially damaging "synergism" as a result of
these combined effects. For example, elastase has been re-
ported to activate latent gelatinase [85] and to inactivate the
major physiological gelatinase inhibitor, TIMP [41, 114]. Should
these actions occur simultaneously in the same microenviron-
ment, the net result would be a dramatic increase in the local
activity of gelatinase and amplification of any effects (positive
or negative) arising from the active enzyme. Clearly similar
synergistic interactions can be postulated for other proteinase/
proteinase inhibitor pairs such as plasmin and alpha-2-antiplas-
mm, and elastase and alpha-l-PI. Furthermore, it should be
pointed out that such synergistic interactions can be effected by
agents other than proteinases. For example, intact glomeruli,
leukocytes, and cultured mesangial cells produce reactive oxy-
gen metabolites (ROM) [reviewed in 122], agents which have
been reported to activate latent gelatinase [123] and inactivate
lIMP-i [124].
A summary of the evidence supporting a role for proteinase-
mediated degradation of non-GBM proteins as a mechanism of
glomerular injury is presented in Table 2.
Proteinase-mediated alterations in glomerular metabolism
and function
In vitro, proteolytic enzymes have been shown to alter the
production by intact cells of a variety of key metabolites,
autocnnes, and immune mediators including: stimulation of the
production of PAF (platelet activating factor) by elastase and
cathepsin G [25]; stimulation of the release of adenine nucleo-
tides by elastase [23]; stimulation of the synthesis of PGI2 by
thrombin, trypsin, and cathepsin G [22, 23]; stimulation of
PGE2 production by elastase [125]; stimulation of Ca2 flux and
1P3 (inositol trisphosphate) synthesis by elastase [26] and
thrombin [27]; and inhibition of thromboxane B2 synthesis by
thrombin [24]. Thrombin has been reported to also stimulate the
production of uPA, tPA, and plasminogen activator inhibitor by
cultured glomerular epithelial cells [29] and to increase the
expression of endothelin in cultured mesangial cells [1261.
However, of particular interest here is the ability of proteinases
to modulate the production of cAMP and reactive oxygen
metabolites (ROM), and to stimulate cell proliferation.
Proteolytic enzymes and the cAMP system. Several recent
studies have suggested an important role for cyclic nucleotides
in glomerular pathophysiology [127, 128]. In addition, extensive
experimental evidence indicates that cAMP/cGMP may modu-
late inflammatory and immune responses in a variety of tissues
[129, 130]. The ability of proteolytic enzymes, including
trypsin, elastase, chymotrypsin, and acrosin to alter in vitro the
activity of enzymes associated with the metabolism of cAMP
and cGMP is well documented [131—137]. In addition, trypsin
and thrombin have been reported to increase the cAMP content
of intact fibroblasts [201 and lymphocytes [136]; and thrombin
increases the cGMP content of cultured neuroblastoma cells
[21]. These changes in cyclic nucleotide metabolism require
active proteinases, are irreversible, and do not appear to result
from inactivation of phosphodiesterases. Although the precise
mechanism of action is presently unclear, cleavage of an
inhibitory G protein has been postulated in at least one case
[135]. Similar effects have been observed in freshly isolated
glomeruli. Shah [138] has reported that thrombin and trypsin
caused a marked increase in the cAMP content of isolated
glomeruli. Thrombin had no effect on the cGMP content of
glomeruli and no effect on either cAMP or cGMP content of
tubules. Thrombin did not affect the cAMP phosphodiesterase
activity of the glomeruli. The glomerular response to DIFP-
treated thrombin was markedly reduced suggesting that proteo-
lytic activity of thrombin is required for the response.
Role of proteolytic enzymes in the production of reactive
oxygen metabolites. Several lines of evidence suggest that
reactive oxygen metabolites (ROM) may play an important
pathogenic role in leukocyte-dependent as well as leukocyte-
independent types of glomerulonephritis [122]. Leukocytes,
including PMN, monocytes, and macrophages are known to
produce ROM in response to a variety of stimuli [139]. The
ability of proteinase inhibitors to inhibit ROM production by
stimulated leukocytes suggests an important role for proteolytic
enzymes in this process. For example, the serine proteinase
inhibitors PMSF, TLCK, TPCK, aprotinin, and SBTI all mark-
edly inhibited ROM production by human PMN and monocytes
stimulated with cytocalasin E or concanavalin A [140]. In
addition, pretreatment of macrophages with proteolytic en-
zymes (elastase, trypsin, or and cathepsin G) resulted in en-
hanced ROM production following stimulation of the pretreated
cells [141, 142].
Isolated glomeruli [143] as well as cultured mesangial cells
[144] have also been shown to generate ROM. Although a role
for proteinases in glomerular ROM production has not been
reported, the similarities between ROM production by glomer-
uli and phagocytic cells suggest that proteinases may also play
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a key role in glomerular ROM production. Indeed, Basci and
Shah [28] have reported that treatment of freshly isolated
glomeruli with trypsin or chymotrypsin results in the produc-
tion of chemiluminescence, a phenomenon usually associated
with ROM. In contrast to glomeruli, tubules had only a minor
chemiluminescence response. Thrombin, bacterial collagenase
and plasmin had no effect on ROM production by glomeruli.
Proteinase-mediated effects on cell proliferation. Several
types of human and experimental glomerular diseases are
characterized by abnormal proliferation of glomerular cells.
Although the mechanisms responsible for such proliferation are
unclear, recently published studies document the ability of
thrombin to stimulate the proliferation of cultured glomerular
cells. He et al [29] have reported that human alpha-thrombin
promoted the proliferation of cultured human glomerular epi-
thelial cells. This effect was inhibited by hirudin (which blocks
both receptor binding and catalytic activity of thrombin) and
DIPF (an irreversible thrombin inhibitor which does not block
receptor binding) indicating that both receptor binding and
catalytic activity are required to produce the effect. Abboud
and coworkers [271 have reported that bovine thrombin caused
a dose dependent increase in DNA synthesis (3H-thymidine
uptake) in cultured human mesangial cells. This effect was
blocked by hirudin and also observed with a highly purified
alpha-thrombin, suggesting that contaminating proteinases
were not responsible for the stimulation of proliferation. The
authors did not examine the effects of DIPF-treated thrombin.
Thus the requirement for receptor binding, catalytic activity or
both cannot be assessed.
Although only a limited number of studies have been carried
out with isolated glomeruli or glomerular cells, these studies
document the ability of proteolytic enzymes to modulate the
production of cAMP and ROM (in both leukocytes and glomer-
uli) and to stimulate the proliferation of glomerular cells in
culture and suggest that this may be an important mechanism of
proteinase-mediated glomerular injury. A summary of the evi-
dence supporting a role for proteinase-mediated alterations in
glomerular metabolism is presented in Table 2.
In vivo studies supporting a pathogenic role for proteolytic
enzymes in experimental models of glomerulonephritis
As discussed above, in vitro studies have documented sev-
eral mechanisms by which proteolytic enzymes may potentially
contribute to glomerular injury. Although such studies are
essential to our understanding of the pathogenesis of glomerular
injury, they do not establish a direct pathogenic role for
proteolytic enzymes in glomerular disease. In contrast, recent
in vivo studies involving leukocyte-dependent and leukocyte-
independent models of glomerulonephritis provide direct evi-
dence for a pathogenic of proteolytic enzymes in glomerular
injury. However, because of the inherent complexity of in vivo
systems, neither the specific proteinases nor their mechanism(s)
of action have been established. Regardless of the mecha-
nism(s), in vivo studies with experimentally-induced glomeru-
lonephritis provide strong support for a pathogenic role for
proteolytic enzymes in both neutrophil-dependent and neutro-
phil-independent glomerular disease.
Renal infusion of elastase or cathepsin G causes proteinuria
in normal rats
One obvious corollary of the proteinase-mediated glomerular
injury hypothesis is that exogenous administration of the ap-
propriate proteolytic enzyme(s) should result in glomerular
injury. Johnson et a! [1451 have reported that infusion of
microgram quantities of either elastase or cathepsin G into the
renal artery of rats resulted in marked proteinuria in the 24 hour
period following the infusion. Only infusion of active elastase
caused proteinuria although both active and irreversibly inacti-
vated elastase localized equally in the glomerular capillary wall.
Rats perfused with cationized IgG failed to develop proteinuria,
establishing that neutralization of the glomerular anionic charge
by the positively charged proteinases (p1 9 to 11) did not
account for the proteinuria. Interestingly, glomeruli from kid-
neys perfused with active elastase were histologically normal
with no foot process fusion and no evidence of inflammatory
cell involvement or endothelial cell damage. Based on these
data and the well-documented ability of elastase and cathepsin
G to degrade GBM and GBM components in vitro (see above),
the authors postulated that the proteinuria arises as a result of
GBM damage by the infused proteinases. While a contribution
from other effects of elastase and cathepsin G (as described
above) can not be ruled out, this study documents the ability of
exogenously administered proteinases to induce proteinuria in
rats and provides strong support for proteinase-mediated GBM
degradation as a mechanism of glomerular injury.
Beige mice do nor develop antiGBM antibody-induced
proteinuria
A second corollary of the proteinase-mediated glomerular
injury hypothesis is that animals which lack a putative glomer-
ular-damaging proteinase should not be susceptible to experi-
mental models of glomerulonephritis involving that proteinase.
Such evidence has recently been provided by Schrijver et al
[1461. These workers compared glomerular injury and protein-
uria resulting from experimentally-induced antiGBM antibody
disease in control and Beige mice, the latter whose PMNs are
deficient in elastase and cathepsin G. Injection of antiGBM
antibodies (IgG fraction) into control mice resulted in a dose-
dependent proteinuria during the 24 hour period immediately
following the injection. In contrast, Beige mice injected with
identical doses of antiGBM antibodies failed to develop pro-
teinuria except at the highest dose of antiGBM IgG tested. With
this dose, they excreted four times as much urinary protein as
uninjected controls but still only 5% of that excreted in the
antiGBM-treated normal mice. Immunofluorescence micros-
copy showed similar deposition of rabbit IgG and mouse
complement component C3 in glomeruli from both groups of
mice following treatment with antiGBM IgG. The failure of
Beige mice to develop proteinuria was not due to lack of
infiltrating PMN. EM demonstrated similar degrees of PMN
attachment to the GBM as well as swelling and necrosis of
endothelial cells in both groups. PMA-stimulated superoxide
production was similar in PMN from Beige and control mice.
Catalase (a scavenger of H,02) and deferoxamine (an iron
chelator which prevents the formation of hydroxyl radical) had
no effect on the proteinuria in control mice treated with
antiGBM IgG, indicating that reactive oxygen metabolites are
168 Baricos and Shah: Proteolytic enzymes and glomerular injury
not involved in the development of proteinuria in this model.
This study clearly demonstrates that Beige mice do not develop
significant proteinuria during the heterologous phase of exper-
imentally-induced antiGBM antibody disease despite a similar
degree of PMN infiltration, and antibody and C3 deposition in
their gloineruli. These latter observations are interesting since
they demonstrate that deposition of antibody and complement
as well as the presence of PMN is not, in itself, sufficient to
cause proteinuria. These data, in combination with the in vitro
and in vivo studies presented above, provide additional support
for proteinase-mediated GBM damage as a mechanism of
proteinuria in the neutrophil-dependent antiGBM antibody dis-
ease model of glomerulonephritis.
Effect of synthetic proteinase inhibitors on pathological
changes in experimental glomerulonephritis
An additional corollary of the proteinase-mediated glomeru-
lar injury hypothesis is that inhibitors of putative glomerular-
damaging proteolytic enzymes should block or attenuate the
pathological changes associated with experimental models of
glomerulonephritis involving those proteinases. Such studies
have been reported for both leukocyte-dependent and leuko-
cyte-independent models of glomerulonephritis.
Cysteine proteinase inhibitors reduce proteinuria in a neutro-
phil- and complement-independent model of antiGBM antibody
disease. Studies from our laboratory have provided evidence
that cysteine proteinases may play a pathogenic role in a
complement- and neutrophil-independent model of antiglomer-
ular basement membrane (GBM) antibody disease [72, 147].
Transepoxysuccinyl-L-leucylamido-(4-guanidino)butane (E-64)
is a specific, irreversible inhibitor of cysteine proteinases. It is:
unreactive with serine, aspartic, or metalloproteinases; does
not react at appreciable rates with low molecular weight thiols
such as glutathione; does not react with nonproteolytic en-
zymes which contain a cysteine at their active site [148, 149];
and is relatively nontoxic [150]. In two separate studies, rats
treated with E-64 and proteinuric doses of neutrophil- and
complement-independent antiGBM IgG excreted significantly
less urinary protein than rats receiving identical doses antiGBM
IgG alone (E-64-treated: —43%, P < 0.001). This reduction in
urinary protein excretion was accompanied by a marked de-
crease in the specific activity of cathepsins B and L in glomeruli
and cortex isolated from rats treated with antiGBM IgG and
E-64 compared to either saline-treated controls or rats treated
with antiGBM IgG alone. Renal function, as assessed by BUN
and plasma creatinine measurements, was unchanged in either
experimental group compared to saline-treated controls.
In a subsequent study [1511 we confirmed and extended these
observations. Rats treated with trans-epoxysuccinyl-L-leucyla-
mido-(3-methyl)butane (Ep475, an E-64 analog) and proteinuric
doses of neutrophil- and complement-independent antiGBM
IgG exhibited significantly reduced proteinuria (—45%, P <
0.05) compared to rats receiving identical doses of antiGBM
IgG only. There was a significant reduction in the activity of
both cathepsin B and cathepsin L in renal cortices obtained
from Ep-475-treated rats compared to either saline-treated
controls or rats treated with antiGBM IgG only. Administration
of Z-Phe-Tyr(O-t-butyl)CHN2 (ZFYCHN2), a specific, irrevers-
ible inhibitor mainly of cathepsin L [152], caused a similar
reduction in proteinuria (—56%, P < 0.05). This reduction in
proteinuria was accompanied by a marked decrease (—84%) in
the specific activity of renal cortical cathepsin L in ZFYCHN2-
treated rats. There was no significant change in: the activity of
renal cortical cathepsin B; renal antiGBM antibody uptake;
plasma urea nitrogen or plasma creatinine values in the
ZFYCHN2-treated rats compared to rats treated with antiGBM
IgG only or saline-treated controls.
The mechanism(s) by which cysteine proteinases may con-
tribute to glomerular injury is presently unclear. As discussed
above, cysteine proteinases are present in normal glomeruli and
can degrade GBM and GBM components in vitro under acid
conditions. The extracellular location of the GBM suggests that
the initial step(s) in GBM degradation must take place at the
neutral pH presumed to exist at the GBM-plasma interface.
Most cysteine proteinases, including cathepsins B and L, are
relatively inactive in vitro at neutral pH, although we have
observed significant degradation of GBM by endogenous gb-
merular cysteine proteinases at pH 6.5 [9]. However, it must be
kept in mind that determination of pH optima in vitro are
dependent on the substrate used as well as the specific condi-
tions of the assay [153]. Furthermore, the ability of certain cells
to acidify their pericellular environment [154] may provide a
mechanism for lysosomal acid proteinases to function in an
extracellular environment. Although calpain [155] and cathep-
sin S [156] are cysteine proteinases which are active at neutral
pH, little is known concerning the presence of these enzymes in
glomeruli or the potential role of these proteinases in GBM
damage or other types of glomerular injury. Thus while a direct
role for cysteine proteinases in GBM degradation remains a
possibility, other mechanisms of cysteine proteinase-mediated
glomerular injury must be considered including inactivation of
proteinase inhibitors [111] and activation of latent proteinases
as previously demonstrated for cathepsin B [102]. Regardless of
the mechanism, the ability of specific cysteine proteinase inhib-
itors to reduce proteinuria in an experimental model of glomer-
ulonephritis indicates an important role for one or more cyste-
me proteinases in this model of glomerular injury.
Serine proteinase inhibitors. Jennette et al [157] have re-
ported a significant reduction (—69% to —89%) in glomerular
necrosis in mice with horse apoferritin (HAF)-induced immune
complex glomerulonephritis that had been treated with amidine-
type inhibitors of trypsin-like proteinases (but which did not
effectively inhibit the complement system). There was no
difference between treated and non-treated groups in the
amount or distribution of IgG, HAP, or C3, as measured by
immunofluorescence staining. In long-term survival studies (33
days) only 3 of 9 inhibitor-treated mice died compared with 7
out of 10 mice in the group receiving HAF only.
Ikehara et al [158] have examined the effect of FUT-175
(6-amidino-2-naphthyl p-guanidinobenzoate dimethanesulpho-
nate), a synthetic proteinase inhibitor of Cir and Cl esterase,
thrombin, plasmin, kallikrein, and trypsin, on the development
of lupus nephritis in (NZBxNZW)F1 mice. High doses of
FUT- 175 (400 mg/kg/day) decreased the incidence of severe
proteinuria (>300 mg/dl), improved renal function (as indicated
by BUN), and decreased immune complex and C3 deposits and
glomerular damage as assessed histologically. FUT-175 had no
effect on ANA titer. Although these inhibitors are specific for
serine proteinases, the fact that they inhibit several serine
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Table 3. In vivo evidence for proteinase-mediated gIomerular injury









































proteinases precludes identification of the specific serine pro-
teinase involved or the mechanism of injury.
A summary of the in vivo evidence supporting proteinase-
mediated glomerular injury is presented in Table 3.
Conclusions and perspective
A large number of in vitro studies provide strong support for
the concept that proteinase-mediated GBM damage may be an
important mechanism of glomerular injury in leukocyte-
dependent as well as leukocyte-independent types of glomeru-
lonephritis. In addition, recent in vitro studies indicate that
proteolytic enzymes may contribute to glomerular injury by
mechanisms independent of GBM damage, including activation
of latent enzymes (such as, plasminogen, metalloproteinases),
inactivation of proteinase inhibitors (alpha- l-proteinase inhibi-
tor, alpha-2-antiplasmin, and tissue inhibitor of metalloprotein-
ases), and proteinase-mediated alterations in glomerular metab-
olism (cAMP, reactive oxygen metabolites, Ca2 and 1P3) and
cell proliferation. It is important to point out that most in vitro
studies have been carried out in simplified systems which lack
proteinase inhibitors and other potentially important modula-
tors known to be present in vivo. Nonetheless, in vitro studies
clearly document the potential of proteolytic enzymes to medi-
ate glomerular injury in vivo and aid in the design and interpre-
tation of in vivo experiments.
In vivo studies utilizing experimental models of glomerulo-
nephritis also support an important role for proteolytic enzymes
in both leukocyte-dependent and independent models of gb-
merular disease. The potential for synergistic interactions
among proteinases, proteinase inhibitors, and other effectors
(for example, reactive oxygen metabolites) complicates the
interpretation of in vivo studies and precludes in most cases the
definitive identification of the specific proteinase involved and
the mechanism(s) by which it produces glomerular injury.
Nonetheless, these studies are in good agreement with the in
vitro studies and provide support for the proteinase-mediated
glomerular injury hypothesis. Clearly, further in vivo studies
are needed to establish which types of glomerular diseases
involve proteolytic enzymes and the identity of the protein-
ase(s) involved. The increasing availability of a variety of
specific proteinase inhibitors suitable for experimental use in
vivo should greatly facilitate such studies.
Glomerular disease is a multifaceted phenomenon resulting
from interactions among diverse biological processes. Our
understanding of the role of proteolytic enzymes in these
processes is just beginning. The recognition that proteolytic
enzymes may mediate gbomerular injury by mechanisms inde-
pendent of GBM damage; that complex interactions can occur
between proteolytic enzymes, their inhibitors, and other ef-
fector systems; and that glomerular-damaging proteolytic en-
zymes may originate from sources other than PMN represent
important conceptual advances in our understanding of the
potential role of proteinases in glomerular injury. These con-
cepts should provide a useful framework for the design and
interpretation of future studies and hopefully enhance our
overall understanding of the pathogenesis of glomerular dis-
ease.
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ROM: reactive oxygen metabolites
APMA: aminophenylmercuric acetate
SBTI: soya bean trypsin inhibitor
alpha- 1 -P1: alpha- 1 -proteinase inhibitor
alpha-2-AP: alpha-2-antiplasmin
PMSF: phenylmethylsulfonylfluroide
TIMP: tissue inhibitor of metalloproteinases
tPA: tissue plasminogen activator
uPA: urokinase-like plasminogen activator
TLCK: tolsyllysyl chloromethyl ketone





PMA: phorbol myristate acetate
PAF: platelet activating factor
ZFYCHN2: Z-Phe-Tyr(O-t-butyl)CHN2
1P3: inositol triphosphate
